SUMMARY:
NRPCs are feasible for clinical research for the treatment of CMT1A patients.
TITLE:
Preclinical Efficacy of Peripheral Nerve Regeneration by Schwann Cell-like Cells Differentiated from Human Tonsil-Derived Mesenchymal Stem Cells in C22 Mice
DESCRIPTION:
Charcot-Marie-Tooth disease (CMT) is a hereditary disease with heterogeneous phenotypes and genetic causes. CMT type 1A (CMT1A) is a type of disease affecting the peripheral nerves and is caused by the duplication of the peripheral myelin protein 22 (PMP22) gene. Human tonsil-derived mesenchymal stem cells (TMSCs) are useful for stem cell therapy in various diseases and can be differentiated into Schwann cell-like cells (TMSC-SCs). We investigated the potential of TMSC-SCs called neuronal…
CONTENT:
Biomedicines. 2023 Dec 17;11(12):3334. doi: 10.3390/biomedicines11123334.
ABSTRACT
Charcot-Marie-Tooth disease (CMT) is a hereditary disease with heterogeneous phenotypes and genetic causes. CMT type 1A (CMT1A) is a type of disease affecting the peripheral nerves and is caused by the duplication of the peripheral myelin protein 22 (PMP22 ) gene. Human tonsil-derived mesenchymal stem cells (TMSCs) are useful for stem cell therapy in various diseases and can be differentiated into Schwann cell-like cells (TMSC-SCs). We investigated the potential of TMSC-SCs called neuronal regeneration-promoting cells (NRPCs) for peripheral nerve and muscle regeneration in C22 mice, a model for CMT1A. We transplanted NRPCs manufactured in a good manufacturing practice facility into the bilateral thigh muscles of C22 mice and performed behavior and nerve conduction tests and histological and ultrastructural analyses. Significantly, the motor function was much improved, the ratio of myelinated axons was increased, and the G-ratio was reduced by the transplantation of NRPCs. The sciatic nerve and gastrocnemius muscle regeneration of C22 mice following the transplantation of NRPCs downregulated PMP22 overexpression, which was observed in a dose-dependent manner. These results suggest that NRPCs are feasible for clinical research for the treatment of CMT1A patients. Research applying NRPCs to other peripheral nerve diseases is also needed.
PMID:38137555 | DOI:10.3390/biomedicines11123334
SOURCE:
Biomedicines
TAGS:
NRPCs
CATEGORY:
Research
SUBCATEGORY:
n/a
DATE – PUBLISHED:
2023-12-18T15:38:13Z
DATE – DOI: 2023-12-18T15:38:13Z
DATE – PUBMED: 2023 Dec 17
DATE OUTPUT MATCHED: True
DATE – ADDED:
Sat, 23 Dec 2023 06:00:00 -0500
DATE – RETRIEVED:
12/23/23 12:43PM
2023-12-23T12:43:06-05:00
FEATURED IMAGE:
Media Uploaded (image/jpeg)
IDENTIFIER:
pmid:38137555,doi:10.3390/biomedicines11123334
PUBMED ID:
pubmed:38137555
DOI:
10.3390/biomedicines11123334
LINK – PUBMED:
https://pubmed.ncbi.nlm.nih.gov/38137555/
LINK – DOI:
https://doi.org/10.3390/biomedicines11123334
LINK – PUBLISHER:
https://www.mdpi.com/2227-9059/11/12/3334
REFERENCES:
CMT Treatment Report, Urgent Research, 2023-12-23T12:43:06-05:00, https://www.cmttreatmentreport.com.
